Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Sign up to receive Sarepta Therapeutics’ e-mail alerts.
Click here to subscribe.
Sarepta Therapeutics – J.P. Morgan 2020 Presentation